Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
OBJECTIVE
To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%).


METHODS
Twenty-seven healthy volunteers were studied. After a 24-h IOP baseline measurement was taken, one ophthalmic solution was applied to the right eye daily for 7 days. The drug was then withdrawn for 2 weeks. The other agent was then applied to the left eye in the same manner. IOP was measured every 3 h for 24 h on the seventh day of treatment.


RESULTS
The 24-h IOP after 7 days' treatment with latanoprost decreased from 11.5 mmHg at baseline to 9.7 mmHg (-1.8 mmHg) and that with tafluprost from 11.8 to 9.8 mmHg (-1.9 mmHg). Tafluprost was statistically more effective after 24 h (P = 0.007; paired t test). The number of subjects with a 24-h mean IOP reduction of <10% was 8/27 (29.6%) with latanoprost versus 4/27 (14.8%) with tafluprost. The incidence of conjunctival hyperemia with latanoprost was 4/27 (14.8%) and that with tafluprost was 8/27 (29.6%).


CONCLUSIONS
The overall efficacies of the two agents were not different, but tafluprost was associated with a greater reduction in IOP at 24 h after administration. Tafluprost showed a higher rate of conjunctival hyperemia.
Mochizuki
Hideki
H
Department of Ophthalmology and Visual Science, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan. mochizuki-h@hiroshima-u.ac.jp
Itakura
Hideki
H
Yokoyama
Tomoko
T
Takamatsu
Michiya
M
Kiuchi
Yoshiaki
Y
D000287:Administration, Topical; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002940:Circadian Rhythm / Q000187:drug effects*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000009:adverse effects; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D014065:Tonometry, Ocular; D014792:Visual Acuity; D055815:Young Adult
D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; C485333:tafluprost; D000077338:Latanoprost